Mirae Asset Global Investments
AVBP icon

Mirae Asset Global Investments’s ArriVent BioPharma AVBP Stock Holding History

Mirae Asset Global Investments’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72.4K Sell
2,083
-70
-3% -$2.07K ﹤0.01% 1306
2026
Q1 		$49.7K Buy
2,153
+147
+7% +$3.32K ﹤0.01% 1297
2025
Q4 		$40.4K Buy
2,006
+438
+28% +$9.12K ﹤0.01% 1438
2025
Q3 		$28.9K Buy
1,568
+246
+19% +$4.83K ﹤0.01% 1442
2025
Q2 		$28.8K Buy
1,322
+194
+17% +$4.03K ﹤0.01% 1345
2025
Q1 		$21.4K Buy
1,128
+5
+0.4% +$122 ﹤0.01% 1384
2024
Q4 		$30.6K Buy
+1,123
New +$32.2K ﹤0.01% 1354

Other funds holding AVBP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

Mirae Asset Global Investments's AVBP Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its ArriVent BioPharma (AVBP) stake by 3.3% in Q2 2026, selling an estimated $2.07K and leaving 2,083 shares worth $72.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1306.

Mirae Asset Global Investments first reported a position in AVBP in Q4 2024 and has held it in 7 quarters since. 40 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Mirae Asset Global Investments held 2,083 shares of ArriVent BioPharma worth $72.4K as of Q2 2026.
  • Mirae Asset Global Investments sold 70 ArriVent BioPharma shares in Q2 2026, an estimated $2.07K.
  • ArriVent BioPharma made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1306 holding.
  • Mirae Asset Global Investments first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 7 quarters since.
  • 40 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.